FIGURE 3.
Subgroup analysis based on type of statin (A) and disease activity (B). A. Atorvastatin produced a greater reduction in DAS28 in RA patients (SMD −0.77, 95% CI [−1.77,−0.36], P = 0.002, I2 = 71%). B. Patients with highly active disease (defined as baseline DAS28 ≥5.1) tended to benefit more from statin therapy compared with patients with moderate and low disease activity (SMD −0.73, 95% CI [−1.28,−0.18], P = 0.01, I2 = 79%). CI = confidence interval, DAS28 = disease activity score in 28 joints, SMD = standardized mean difference.